Evidence map›Paper›PMID 36243845›Full record

ArticleCurrent topics in microbiology and immunology2022

Control of CD4

Benjamin Cameron, Syed Aymaan Zaheer, Margarita Dominguez-Villar

Abstract read
PubMed Publisher
In one paragraph

Article in Current topics in microbiology and immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Benjamin CameronFaculty of Medicine, Imperial College London, London, W2 1PG, UK.
Syed Aymaan ZaheerFaculty of Medicine, Imperial College London, London, W2 1PG, UK.
Margarita Dominguez-VillarFaculty of Medicine, Imperial College London, London, W2 1PG, UK. m.dominguez-villar@imperial.ac.uk.
Imperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The phosphoinositide-3-kinase (PI3K) pathway is a highly conserved intracellular signaling pathway involving numerous key effectors which, in response to diverse extracellular stimuli, modulate the phenotype and function of most mammalian cell types in a pleiotropic manner. PI3K signaling plays a critical role in the development, activation, and differentiation of lymphocytes. In particular, the PI3Kδ and PI3Kγ isoforms have been shown to carry out essential, non-redundant roles in T cells, and therefore, tight regulation of the PI3K pathway is important to maintain the balance between immune tolerance and inflammation. Recent and ongoing efforts to manipulate the biology of T helper cell subsets in the treatment of autoimmune conditions, inflammatory disorders, as well as cancer have shown promising results, and targeting the PI3K pathway may be beneficial in these contexts. However, more insight as to the precise function of individual PI3K isoforms in pathogenic and protective immune cell subsets is still required, and how exactly PI3K signaling is regulated and integrated with classical immune pathways. This chapter provides an overview of the role of PI3K isoforms in the differentiation and function of T helper cell subsets, within the broader context of targeting this pathway to potentially alleviate immunopathology.

Indexed as

Phosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesAnimalsCell DifferentiationMammalsPhosphatidylinositolsProtein IsoformsT-Lymphocytes, Helper-InducerPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesPhosphatidylinositolsProtein IsoformsAutoimmunityCD4+ T cellsDifferentiationHelper T cellsInflammationmTORPhosphoinositide-3-kinasePI3K isoforms

Identifiers

PMID36243845
OpenAlexW4306362009

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.